

**SWOG Translational Medicine Mini-Retreat**  
***“Liquid Biopsies: Using Cell-Free DNA Methodologies to Assess Clinical Trial Outcomes”***

Thursday October 4, 2018  
6:00pm – 9:00pm  
Hyatt Regency, Chicago IL  
Crystal BC (Lobby Level, West Tower)

***Open to All Members***

\*\*\*

***Registration Required***

\*\*\*

***Sponsored by The Hope Foundation***

**6:00pm - 6:05pm**

***“Welcome and Introductions”***

James M Rae, PhD  
Rogel Cancer Center  
University of Michigan

**6:05pm-7:05pm**

**Session 1**

**“How to Choose the Right Platform for Your Clinical Trial”**

Chair: Honey V. Reddi, PhD, FACMG  
Clinical Laboratory Director  
The Jackson Laboratory for Genomic Medicine

**Speakers:**

- 1) Honey V Reddi, PhD, FACMG  
Clinical Laboratory Director  
The Jackson Laboratory for Genomic Medicine  
**Title:** *Technical Considerations for Taking Liquid Biopsy to the Clinic*
  
- 2) Philip C. Mack, PhD  
Director of Molecular Pharmacology  
UC Davis Comprehensive Cancer Center  
**Title:** *Clinical Utility of ctDNA Analysis*
  
- 3) Funda Meric-Bernstam, MD  
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine  
University of Texas MD Anderson Cancer Center  
**Title:** *Opportunities and Challenges of Incorporating cfDNA into Clinical Trials*

**7:05pm – 8:05pm**

**Session 2**

**Novel trial designs with ctDNA**

Chair: Dan Levy, PhD

Cold Spring Harbor Laboratory

Speakers:

- 1) Alex Herrera, MD  
Beckman Research Institute  
City of Hope  
**Title:** *Incorporating ctDNA into Lymphoma Clinical Trials*
  
- 2) Van K. Morris, MD  
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine  
University of Texas, MD Anderson Cancer Center  
**Title:** *ctDNA as a Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colon Cancer*
  
- 3) Filip Janku, MD, PhD  
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine,  
University of Texas, MD Anderson Cancer Center  
**Title:** *Liquid Biopsies in Personalized Medicine Strategies in Early Phase Clinical Trials*

**8:00-8:15pm**

**Break**

**8:15pm – 9:00pm**

**Session 3**

**“Commercial ctDNA Platforms”**

Chair: Lee Ellis, MD, FASCO

SWOG Vice Chair for Translational Medicine

Speakers:

- 1) Guardant Health, Inc.  
San Jose, CA  
Becky Nagy, MS LGC  
Director, Medical Affairs  
**Title:** *Cell-free DNA Analysis to Assess Tumor Genomics*

- 2) PGDx, Personal Genome Diagnostics, Inc.  
Baltimore, MD  
Luis A. Diaz, MD  
Chief, Division of Solid Tumor Oncology  
Memorial Sloan Kettering Cancer Center  
**Title:** *New Insights in Clinical Application of ctDNA*
  
- 3) Foundation Medicine, Inc.  
Boston, MA  
Jon Chung, Senior Manager, Clinical Development  
**Title:** *Hybrid Capture-based Genomic Profiling of ctDNA to Assess Genomic Alterations and Tumor Mutational Burden*
  
- 4) DiaCarta, Inc.  
Richmond, CA  
Paul Okunieff, MD  
Professor and Chair, Department of Radiation Oncology  
University of Florida College of Medicine  
**Title:** *Using XNA Clamps as Liquid Biopsies for Screening, Follow up Evaluation, and for Personalized Quantitative Measurement of Drug Response*